



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**14.10.2015 Bulletin 2015/42**

(51) Int Cl.:  
**C12P 21/04** (2006.01) **C12P 21/06** (2006.01)  
**C12N 15/113** (2010.01) **C12N 9/24** (2006.01)

(21) Application number: **15163041.5**

(22) Date of filing: **13.10.2008**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR**

(30) Priority: **12.10.2007 US 979483 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:  
**08838267.6 / 2 195 444**

(71) Applicant: **Sigma-Aldrich Co. LLC**  
**St. Louis, MO 63103 (US)**

(72) Inventors:  
• **Zhang, Min**  
**St. Louis, MO 63103 (US)**

• **Ross, James S.**  
**St. Louis, 63103 (US)**

(74) Representative: **Spinner, David Richard**  
**Greaves Brewster LLP**  
**Copa House**  
**Station Road**  
**Cheddar, Somerset BS27 3AH (GB)**


Remarks:

This application was filed on 09-04-2015 as a divisional application to the application mentioned under INID code 62.

(54) **CELL LINE AND METHODS FOR IMPROVED GLYCOPROTEIN SIALYLATION**

(57) The present invention provides compositions and methods for the production of glycoproteins with enhanced sialylation. In particular, the invention provides

cell lines comprising disrupted sialidase expression and methods of using the cell lines to produce glycoproteins with enhanced sialylation.



**FIG. 1**

**Description****FIELD OF THE INVENTION**

**[0001]** The present invention generally relates to sialidases. In particular, the invention relates to compositions and methods for improving the sialylation of glycoproteins.

**BACKGROUND OF THE INVENTION**

**[0002]** Glycoproteins produced by mammalian cell culture using recombinant DNA technology represent an important category of therapeutic pharmaceuticals for human health care. The biological functions of glycoproteins are often highly dependent upon their carbohydrate structures. Of the numerous sugars found in glycoproteins, the terminal sialic acid is considered particularly important. Sialic acid has been found to influence the solubility, thermal stability, resistance to protease attack, antigenicity, and specific activity of various glycoproteins. The amount of sialic acid in a glycoprotein is the result of two opposing process, i.e., the intracellular addition of sialic acid by sialyltransferase activity and the extra-cellular removal of sialic acid by sialidase cleavage.

**[0003]** When terminal sialic acid is removed from serum glycoproteins, the desialylated proteins have significantly lower circulatory half-lives as compared to the sialylated counterparts. Removal of sialic acid from other glycoproteins correlates with decreased biological activity and increased serum clearance. Additionally, during the production of glycoproteins by cells in batch culture, nutrient consumption and product accumulation may alter the cellular environment such that protein glycosylation decreases over time. Furthermore, the resultant glycoproteins tend to have glycoform heterogeneity and there is significant batch-to-batch variation in the production processes. Such changes are unacceptable in a bioprocess used for the large-scale production of protein therapeutic agents. Therefore, in mammalian cell culture systems it is often desirable to maximize the final sialic acid content of a glycoprotein product to ensure its quality and consistency as an effective pharmaceutical. A need exists, therefore, for a mammalian cell culture system that has enhanced glycoprotein sialylation. Such a system would improve the production of adequately sialylated recombinant glycoproteins.

**SUMMARY OF THE INVENTION**

**[0004]** Among the various aspects of the invention is the provision of a cell line comprising disrupted expression of at least one chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase. The amino acid sequence of the non-cytoplasmic sialidase whose expression is disrupted is selected from the group consisting of (a) at least about 95% identical to SEQ ID NO:2, and (b) at least about 80% identical to SEQ ID NO:4.

**[0005]** Another aspect of the invention encompasses a method for producing a glycoprotein. The method comprises expressing a nucleic acid sequence encoding the glycoprotein in a cell comprising disrupted expression of at least one chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase, wherein the glycoprotein has increased sialylation relative to a suitable control. The amino acid sequence of the non-cytoplasmic sialidase whose expression is disrupted in the cell is selected from the group consisting of (a) at least about 95% identical to SEQ ID NO:2, and (b) at least about 80% identical to SEQ ID NO:4.

**[0006]** A further aspect of the invention provides an isolated nucleic acid encoding a polypeptide whose amino acid sequence consists of SEQ ID NO:2.

**[0007]** Still another aspect of the invention encompasses an isolated nucleic acid encoding a polypeptide whose amino acid sequence consists of SEQ ID NO:4.

**[0008]** Another alternate aspect of the invention provides for a purified polypeptide whose the amino acid sequence consists of SEQ ID NO:2.

**[0009]** A further aspect of the invention encompasses a purified polypeptide whose amino acid sequence consists of SEQ ID NO:4.

**[0010]** Other aspects and features of the invention are described in more below.

**REFERENCE TO COLOR FIGURES**

**[0011]** The application file contains at least one photograph executed in color. Copies of this patent application publication with color photographs will be provided by the Office upon request and payment of the necessary fee.

**DESCRIPTION OF THE FIGURES**

**[0012]**

**Figure 1** illustrates the sialidase activity of the proteins encoded by the CHO Neu1, Neu2, and Neu3 genes. Presented is the enzyme activity in lysates of cells transfected with expression constructs containing the coding region of each gene, as indicated (or any empty expression construct).

**Figure 2** illustrates the inhibition of the sialidase activity of proteins encoded by the CHO Neu1, Neu2, and Neu3 genes. Presented is the enzyme activity measured in the absence or presence of two concentrations of two different sialidase inhibitors in lysates of cells transfected with expression constructs containing the coding region of each gene.

**Figure 3** presents the subcellular locations of the Neu1, Neu2, and Neu3 proteins. Presented are confocal fluorescence microscopy images in which the FLAG-tagged Neu proteins are shown in green, a lysosomal (Lys) marker is shown in red, and a plasma membrane (PM) marker is shown in blue.

**Figure 4** illustrates knock down of the expression of the Neu1, Neu2, and Neu3 mRNAs using small interfering RNA (siRNA) technology. Presented are the products amplified via RT-PCR using gene specific primers after knockdown of each gene with gene specific siRNAs (S1 - S5) or a control siRNA targeting an unrelated GFP nucleic acid sequence (C). The expression of a control gene (beta-2 microglobulin,  $\beta 2M$ ) was not affected by the siRNAs.

**Figure 5** illustrates knock down expression of (A) Neu1, (B) Neu2, and (C) Neu3 mRNA using small interfering RNA (siRNA) technology. Presented are the Q-RT PCR results showing the relative expression of each gene when using siRNAs specific for each Neu gene or a control siRNA targeting an unrelated nucleic acid sequence (GFP).

**Figure 6** illustrates the sialidase activity in CHO-hIFN $\gamma$  cells in which Neu gene expression was knocked down using siRNAs. Presented is the sialidase activity in CHO-hIFN $\gamma$  cells in which each Neu gene was silenced, two Neu genes were silenced, or all Neu genes were silenced. Also shown is the sialidase activity in CHO-hIFN $\gamma$  cells that lacked siRNA constructs (CHO) or comprised a control siRNA targeting an unrelated nucleic acid sequence (GFP).

**Figure 7** illustrates stable knock down of (A) Neu1, (B) Neu2, and (C) Neu3 mRNA expression using short hairpin RNA (shRNA) technology. Presented are the Q-RT PCR results showing the relative expression of each sialidase gene in the corresponding knocked down CHO-hIFN $\gamma$  cells or control CHO-hIFN $\gamma$  cells (non-target), which comprised a control siRNA targeting an unrelated nucleic acid sequence.

**Figure 8** illustrates the stable knock down of sialidase activity in CHO-hIFN $\gamma$  cells using shRNAs. Presented is the sialidase activity in CHO-hIFN $\gamma$  cells in which each of the sialidase genes (Neu1, Neu2, or Neu3) was silenced. Also shown is sialidase activity in control CHO-hIFN $\gamma$  cells (non-target), which comprised a control shRNA targeting an unrelated nucleic acid sequence. \*  $p < 0.005$ , \*\*  $p < 0.0001$ .

**Figure 9** illustrates that cell growth was not affected by sialidase gene silencing. Presented is cell growth (i.e., viable cell density (VCD) and percent viability) as a function of days in culture. Growth data are plotted for CHO-hIFN $\gamma$  cells in which each sialidase gene (Neu1, Neu2, or Neu3) was knocked down or control (non-target) CHO-hIFN $\gamma$  cells (which comprised a control shRNA targeting an unrelated nucleic acid sequence).

**Figure 10** illustrates that production of human interferon gamma (hIFN $\gamma$ ) was not affected by sialidase gene silencing. Plotted is the level of hIFN $\gamma$  protein produced by CHO-hIFN $\gamma$  cells in which each sialidase gene (Neu1, Neu2, or Neu3) was knocked down or control (non-target) CHO-hIFN $\gamma$  cells.

**Figure 11** illustrates that sialidase knocked down cells produce glycoproteins with increased levels of sialic acid. Plotted is the concentration of sialic acid in human interferon gamma (hIFN $\gamma$ ) produced by CHO-hIFN $\gamma$  cells in which each sialidase gene (Neu1, Neu2, or Neu3) was knocked down or control (non-target) CHO-hIFN $\gamma$  cells (which comprised a control shRNA targeting an unrelated nucleic acid sequence). NS, not significant, \*  $p < 0.01$ , \*\*  $p < 0.05$ .

## DETAILED DESCRIPTION OF THE INVENTION

**[0013]** Sialidases are enzymes that remove the terminal sialic acid residue from glycoproteins and glycolipids. Chinese hamster ovary (CHO) cells are known to contain a cytoplasmic sialidase. The inventors of the present invention have isolated and characterized two additional sialidases in CHO cells, i.e., a lysosomal sialidase and a plasma membrane-associated sialidase. Accordingly, the present invention provides cell lines comprising disrupted expression of the two newly identified sialidase genes, either alone, in combination with each other, or in combination with the cytoplasmic sialidase. The invention also provides methods for producing glycoproteins of interest using cells comprising disrupted sialidase expression. In general, glycoproteins produced by the methods of the invention have increased sialic acid content relative to those produced in parental cells having normal sialidase activity.

### (I) Non-cytoplasmic Sialidases

**[0014]** One aspect of the present invention encompasses an isolated nucleic acid sequence encoding a polypeptide whose amino acid sequence consists of SEQ ID NO:2. In general, the isolated nucleic acid sequence is at least about 80% identical to SEQ ID NO:1. In some embodiments, isolated nucleic acid sequence may be about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to SEQ ID NO:1. In other embodiments, the isolated nucleic acid sequence may consist essentially of SEQ ID NO:1. In these embodiments, there may be additional

extraneous nucleotides sequences flanking the 5' end, 3' end, or both ends of the isolated nucleic acid sequence. The extraneous nucleotides sequences may be linkers comprising restriction endonuclease cleavage sites for cloning, linkers that are complementary to primers for amplification and/or other detection methods, and the like. In still other embodiments, the isolated nucleic acid sequence may consist of SEQ ID NO:1.

**[0015]** Another aspect of the invention provides an isolated nucleic acid sequence encoding a polypeptide whose amino acid sequence consists of SEQ ID NO:4. In general, the isolated nucleic acid sequence is at least about 80% identical to SEQ ID NO:3. In some embodiment, isolated nucleic acid sequence may be about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to SEQ ID NO:3. In other embodiments, the isolated nucleic acid sequence may consist essentially of SEQ ID NO:3. In these embodiments, there may be additional extraneous nucleotides sequences flanking the 5' end, 3' end, or both ends of the isolated nucleic acid sequence. The extraneous nucleotides sequences may be linkers comprising restriction endonuclease cleavage sites for cloning, linkers that are complementary to primers for amplification and/or other detection methods, and the like. In still other embodiments, the isolated nucleic acid sequence may consist of SEQ ID NO:3.

**[0016]** A further aspect of the invention encompasses a purified polypeptide whose amino acid sequence may be at least about 95% identical to the amino acid sequence of SEQ ID NO:2, wherein the purified polypeptide has sialidase enzyme activity. In some embodiments, the amino acid sequence of the purified polypeptide may be about 95, 96, 97, 98, 99, or 99.5% identical to the amino acid sequence of SEQ ID NO:2. In other embodiments, the amino acid sequence of the purified polypeptide may consist essentially of SEQ ID NO:2. In these embodiments, there may be extraneous amino acid sequences flanking the amino-terminal end, carboxyl-terminal end, or both ends of the purified polypeptide, wherein the biological activity of the purified polypeptide is not altered. These extraneous amino acid sequences may include, but are not limited to, an antibody epitope tag, such as a FLAG tag, a myc tag, a 6xHis tag, an HA tag, a GST tag, a HSV tag, and the like. In a further embodiment, the amino acid sequence of the purified polypeptide may consist of SEQ ID NO:2. Typically the polypeptide encoded by SEQ ID NO:2 (or a related polypeptide) is localized to the lysosomes of a eukaryotic cell.

**[0017]** Still another aspect of the invention provides a purified polypeptide whose amino acid sequence may be at least about 80% identical to the amino acid sequence of SEQ ID NO:4, wherein the purified polypeptide has sialidase enzyme activity. In some embodiments, the amino acid sequence of the purified polypeptide may be about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to the amino acid sequence of SEQ ID NO:4. In other embodiments, the amino acid sequence of the purified polypeptide may consist essentially of SEQ ID NO:4. In these embodiments, there may be extraneous amino acid sequences flanking the amino-terminal end, carboxyl-terminal end, or both ends of the purified polypeptide, wherein the biological activity of the purified polypeptide is not altered. These extraneous amino acid sequences may include, but are not limited to, an antibody epitope tag, such as a FLAG tag, a myc tag, a 6xHis tag, an HA tag, a GST tag, a HSV tag, and the like. In a further embodiment, the amino acid sequence of the purified polypeptide may consist of SEQ ID NO:4. Typically the polypeptide encoded by SEQ ID NO:2 (or a related polypeptide) is localized to the plasma membrane of a eukaryotic cell.

### ***(II) Cell Lines Comprising Disrupted Sialidase Expression***

**[0018]** Another aspect of the invention provides cell lines in which the expression of at least one endogenous, chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase is disrupted, such that the cell line has reduced sialidase enzyme activity. The cell lines may further comprise disrupted expression of an endogenous, chromosomally integrated nucleic acid sequence encoding a cytoplasmic sialidase.

**[0019]** In some embodiments, the cell line comprises disrupted expression of at least one chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase, wherein the amino acid sequence of the sialidase is selected from the group consisting of (a) at least about 95% identical to SEQ ID NO:2, and (b) at least about 80% identical to SEQ ID NO:4. In some embodiments, the non-cytoplasmic sialidase whose expression is disrupted may be about 95, 96, 97, 98, 99, or 99.5% identical to SEQ ID NO:2. In another embodiment, the non-cytoplasmic sialidase whose expression is disrupted may consist essentially of SEQ ID NO:2. In a further embodiment, the non-cytoplasmic sialidase whose expression is disrupted may consist of SEQ ID NO:2. In other embodiments, the non-cytoplasmic sialidase whose expression is disrupted may be about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to the amino acid sequence of SEQ ID NO:4. In an alternate embodiment, the non-cytoplasmic sialidase whose expression is disrupted may consist essentially of SEQ ID NO:4. In a further embodiment, the non-cytoplasmic sialidase whose expression is disrupted may consist of SEQ ID NO:4.

**[0020]** In some iterations, the cell line may have disrupted expression of one non-cytoplasmic sialidase. For example, the expression of the lysosomal sialidase (i.e., related to SEQ ID NO:2) may be disrupted. Alternatively, the expression of the plasma membrane-associated sialidase (i.e., related to SEQ ID NO:4) may be disrupted. In other iterations, the cell line may have disrupted expression of both non-cytoplasmic sialidases. That is, the expression of the lysosomal sialidase (i.e., related to SEQ ID NO:2) and the plasma membrane-associated sialidase (i.e., related to SEQ ID NO:4)

may be both disrupted.

**[0021]** In alternate embodiments, the cell line may further comprise disrupted of a chromosomally integrated nucleic acid sequence encoding a cytoplasmic sialidase, the amino acid sequence of which may be at least about 85% identical to SEQ ID NO:5. In some embodiments, the cytoplasmic sialidase whose expression is disrupted may be about 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to the amino acid sequence of SEQ ID NO:5. In a further embodiment, the cytoplasmic sialidase whose expression is disrupted may consist essentially of SEQ ID NO:5. In yet another embodiment, the cytoplasmic sialidase whose expression is disrupted may consist of SEQ ID NO:5.

**[0022]** In certain iterations, the cell line may have disrupted expression of one non-cytoplasmic sialidase and the cytoplasmic sialidase. For example, the expression of the lysosomal sialidase (i.e., related to SEQ ID NO:2) and the cytoplasmic (i.e., related to SEQ ID NO:5) may be disrupted. Alternatively, the expression of the plasma membrane-associated sialidase (i.e., related to SEQ ID NO:4) and the cytoplasmic (i.e., related to SEQ ID NO:5) may be disrupted. In certain other iterations, the cell line may have disrupted expression of both non-cytoplasmic sialidases and the cytoplasmic sialidase. That is, the expression of the lysosomal sialidase (i.e., related to SEQ ID NO:2), the plasma membrane-associated sialidase (i.e., related to SEQ ID NO:4), and the cytoplasmic (i.e., related to SEQ ID NO:5) all may be disrupted.

#### (a) cell types

**[0023]** In general, eukaryotic cells will be used in the practice of the invention. Suitable host cells include fungi or yeast, such as *Pichia pastoris* or *Saccharomyces cerevisiae*; insect cells, such as SF9 cells from *Spodoptera frugiperda* or S2 cells from *Drosophila melanogaster*, plant cells; and animal cells, such as mouse, rat, hamster, non-human primate, or human cells. Examples of suitable cell lines include Chinese hamster ovary (CHO) cells, monkey kidney CVI line transformed by SV40 (COS7); human embryonic kidney line 293; baby hamster kidney cells (BHK); mouse sertoli cells (TM4); monkey kidney cells (CVI-76); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor cells (MMT); rat hepatoma cells (HTC); HIH/3T3 cells, and TRI cells. For an extensive list of mammalian cell lines, those of ordinary skill in the art may refer to the American Type Culture Collection catalog (ATCC®, Manassas, VA). In general, the cells may be of a variety of cell types, e.g., fibroblast, myoblast, T or B cell, macrophage, epithelial cell, and so forth. In preferred embodiments, the cells are of a type that is widely used for the production of glycoproteins. In an exemplary embodiment, the cells may be CHO cells. Numerous CHO cell lines, some of which produce a glycoprotein of interest, are available from ATCC. Examples of CHO cells that stably express a glycoprotein of interest include CHO-ICAM-1 cells, which produce intracellular cell adhesion molecule-1, and CHO-hIFN $\gamma$  cells, which produce human interferon gamma.

#### (b) disrupted expression

**[0024]** In general, the cell lines of the invention have reduced sialidase expression. The expression may be disrupted at several different steps during gene expression. For example, the DNA sequence encoding the sialidase polypeptide may be altered such that functional messenger RNA (mRNA) (and, consequently, a functional polypeptide) is not made. Alternatively, the mRNA may be altered (or degraded) such that the polypeptide is not made or reduced levels of the polypeptide are made.

##### (i) RNA interference

**[0025]** Sialidase expression may be disrupted using an RNA interference (RNAi) agent that inhibits expression of a target mRNA or transcript. The RNAi agent may lead to cleavage of the target transcript. Alternatively, the RNAi agent may prevent or disrupt translation of the target transcript into a protein.

**[0026]** In some embodiments, the RNAi agent may be a short interfering RNA (siRNA). In general, a siRNA comprises a double-stranded RNA molecule that ranges from about 15 to about 29 nucleotides in length. The siRNA may be about 16-18, 17-19, 21-23, 24-27, or 27-29 nucleotides in length. In a preferred embodiment, the siRNA may be about 21 nucleotides in length. The siRNA may optionally further comprise one or two single-stranded overhangs, e.g., a 3' overhang on one or both ends. The siRNA may be formed from two RNA molecules that hybridize together or, alternatively, may be generated from a short hairpin RNA (shRNA) (see below). In some embodiments, the two strands of the siRNA may be completely complementary, such that no mismatches or bulges exist in the duplex formed between the two sequences. In other embodiments, the two strands of the siRNA may be substantially complementary, such that one or more mismatches and/or bulges may exist in the duplex formed between the two sequences. In certain embodiments, one or both of the 5' ends of the siRNA may have a phosphate group, while in other embodiments one or both of the 5' ends may lack a phosphate group. In other embodiments, one or both of the 3' ends of the siRNA may have a hydroxyl

group, while in other embodiments one or both of the 5' ends may lack a hydroxyl group.

**[0027]** One strand of the siRNA, which is referred to as the "antisense strand" or "guide strand," includes a portion that hybridizes with the target transcript. In preferred embodiments, the antisense strand of the siRNA may be completely complementary with a region of the target transcript, i.e., it hybridizes to the target transcript without a single mismatch or bulge over a target region between about 15 and about 29 nucleotides in length, preferably at least 16 nucleotides in length, and more preferably about 18-20 nucleotides in length. In other embodiments, the antisense strand may be substantially complementary to the target region, i.e., one or more mismatches and/or bulges may exist in the duplex formed by the antisense strand and the target transcript. Typically, siRNAs are targeted to exonic sequences of the target transcript. Those of skill in the art are familiar with programs, algorithms, and/or commercial services that design siRNAs for target transcripts. An exemplary example is the Rosetta siRNA Design Algorithm (Rosetta Inpharmatics, North Seattle, WA) and MISSION® siRNA (Sigma-Aldrich, St. Louis, MO). The siRNA may be enzymatically synthesized *in vitro* using methods well known to those of skill in the art. Alternatively, the siRNA may be chemically synthesized using oligonucleotide synthesis techniques that are well known in the art.

**[0028]** In other embodiments, the RNAi agent may be a short hairpin RNA (shRNA). In general, a shRNA is an RNA molecule comprising at least two complementary portions that are hybridized or are capable of hybridizing to form a double-stranded structure sufficiently long to mediate RNA interference (as described above), and at least one single-stranded portion that forms a loop connecting the regions of the shRNA that form the duplex. The structure may also be called a stem-loop structure, with the stem being the duplex portion. In some embodiments, the duplex portion of the structure may be completely complementary, such that no mismatches or bulges exist in the duplex region of the shRNA. In other embodiments, the duplex portion of the structure may be substantially complementary, such that one or more mismatches and/or bulges may exist in the duplex portion of the shRNA. The loop of the structure may be from about 1 to about 20 nucleotides in length, preferably from about 4 to about 10 about nucleotides in length, and more preferably from about 6 to about 9 nucleotides in length. The loop may be located at either the 5' or 3' end of the region that is complementary to the target transcript (i.e., the antisense portion of the shRNA).

**[0029]** The shRNA may further comprise an overhang on the 5' or 3' end. The optional overhang may be from about 1 to about 20 nucleotides in length, and more preferably from about 2 to about 15 nucleotides in length. In some embodiments, the overhang may comprise one or more U residues, e.g., between about 1 and about 5 U residues. In some embodiments, the 5' end of the shRNA may have a phosphate group, while in other embodiments it may not. In other embodiments, the 3' end of the shRNA may have a hydroxyl group, while in other embodiments it may not. In general, shRNAs are processed into siRNAs by the conserved cellular RNAi machinery. Thus, shRNAs are precursors of siRNAs and are similarly capable of inhibiting expression of a target transcript that is complementary of a portion of the shRNA (i.e., the antisense portion of the shRNA). Those of skill in the art are familiar with the available resources (as detailed above) for the design and synthesis of shRNAs. An exemplary example is MISSION® shRNAs (Sigma-Aldrich).

**[0030]** In still other embodiments, the RNAi agent may be an RNAi expression vector. Typically, an RNAi expression vector may be used for intracellular (*in vivo*) synthesis of RNAi agents, such as siRNAs or shRNAs. In one embodiment, two separate, complementary siRNA strands may be transcribed using a single vector containing two promoters, each of which directs transcription of a single siRNA strand (i.e., each promoter is operably linked to a template for the siRNA so that transcription may occur). The two promoters may be in the same orientation, in which case each is operably linked to a template for one of the complementary siRNA strands. Alternatively, the two promoters may be in opposite orientations, flanking a single template so that transcription for the promoters results in synthesis of two complementary siRNA strands. In another embodiment, the RNAi expression vector may contain a promoter that drives transcription of a single RNA molecule comprising two complementary regions, such that the transcript forms a shRNA.

**[0031]** Those of skill in the art will appreciate that it is preferable for siRNA and shRNA agents to be produced *in vivo* via the transcription of more than one transcription unit. Generally speaking, the promoters utilized to direct *in vivo* expression of the one or more siRNA or shRNA transcription units may be promoters for RNA polymerase III (Pol III). Certain Pol III promoters, such as U6 or H1 promoters, do not require cis-acting regulatory elements within the transcribed region, and thus, are preferred in certain embodiments. In other embodiments, promoters for Pol II may be used to drive expression of the one or more siRNA or shRNA transcription units. In some embodiments, tissue-specific, cell-specific, or inducible Pol II promoters may be used.

**[0032]** A construct that provides a template for the synthesis of siRNA or shRNA may be produced using standard recombinant DNA methods and inserted into any of a wide variety of different vectors suitable for expression in eukaryotic cells. Guidance may be found in Current Protocols in Molecular Biology (Ausubel et al., John Wiley & Sons, New York, 2003) or Molecular Cloning: A Laboratory Manual (Sambrook & Russell, Cold Spring Harbor Press, Cold Spring Harbor, NY, 3rd edition, 2001). Those of skill in the art also appreciate that vectors may comprise additional regulatory sequences (e.g., termination sequence, translational control sequence, etc.), as well selectable marker sequences. DNA plasmids are known in the art, including those based on pBR322, PUC, and so forth. Since many expression vectors already contain a suitable promoter or promoters, it may be only necessary to insert the nucleic acid sequence that encodes the

RNAi agent of interest at an appropriate location with respect to the promoter(s). Viral vectors may also be used to provide intracellular expression of RNAi agents. Suitable viral vectors include retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated virus vectors, herpes virus vectors, and so forth. In preferred embodiment, the RNAi expression vector is a shRNA lentiviral-based vector or lentiviral particle, such as that provided in MISSION® TRC shRNA products (Sigma-Aldrich).

**[0033]** The RNAi agents or RNAi expression vectors may be introduced into the cell using methods well known to those of skill in the art. Guidance may be found in Ausubel et al., *supra* or Sambrook & Russell, *supra*, for example. In some embodiments, the RNAi expression vector, e.g., a viral vector, may be stably integrated into the genome of the cell, such that sialidase expression is disrupted over subsequent cell generations.

#### (ii) gene targeting

**[0034]** In other embodiments, homologous recombination techniques may be used to disrupt sialidase expression at the level of the genomic DNA. Accordingly, these techniques may be used to delete a nucleic acid sequence, delete a portion of a nucleic acid sequence, or introduce point mutations in the nucleic acid sequence, such that no functional product may be made. In one embodiment, the nucleic acid sequence may be targeted by homologous recombination using the techniques of Capecchi (Cell 22:4779-488, 1980) and Smithies (Proc Natl Acad Sci USA 91:3612-3615, 1994). In other embodiments, the nucleic acid sequence may be targeted using a *Cre-loxP* site-specific recombination system, a Flp-FRT site-specific recombination system, or variants thereof. Such recombination systems are commercially available, and additional guidance may be found in Ausubel et al., *supra*. In still another embodiment, the gene may be targeted using zinc finger nuclease (ZFN)-mediated gene targeting (Sangamo Biosciences, Richmond, CA). Briefly, ZFNs are synthetic proteins comprising an engineered zinc finger DNA-binding domain fused to the cleavage domain of the FokI restriction endonuclease. ZFNs may be used to induce double-stranded breaks in specific DNA sequences and thereby promote site-specific homologous recombination and targeted manipulation of genomic sequences. ZFNs may be engineered to target any DNA sequence of interest.

#### (iii) measuring disrupted expression

**[0035]** The RNAi and gene targeting methods described above will generally lead to decreased expression of the sialidase gene(s) and, consequently, decreased sialidase enzyme activity. Accordingly, the cells will generally have reduced levels of sialidase mRNA and/or sialidase protein. A wide variety of methods known in the art may be used to measure mRNA levels, protein levels, or enzyme activity. Non-limiting examples of RNA detection methods include reverse transcriptase PCR, reverse transcriptase quantitative PCR, nucleic acid microarrays, hybridization-based methods, branched DNA detection technologies, Northern blotting, and nuclease protection assays. Non-limiting examples of protein detection methods include Western blotting, ELISA assays, and other immunoassays. Depending upon the specificity of the probes used in these detection assays, each type of sialidase may be detected singly or all three may be detected simultaneously. Regardless of the specificity, however, a decrease in the level of expression may be determined by comparing the levels (of mRNA and/or protein) in a cell with disrupted sialidase expression to those in an untreated cell. Preferably the decrease in sialidase expression results in a decrease in sialidase enzyme activity in the cells (e.g., in a lysate obtained from the cells), in the medium in which the cells were cultured, or both. Sialidase enzyme activity may be measured using a variety of sialidase assays known in the art. For example, sialidase activity may be measured using the assay described in Example 2.

**[0036]** In some embodiments, the levels of sialidase mRNA(s) may be reduced by at least 2-fold, at least 5-fold, at least 10-fold, at least 100-fold, at least 1000-fold, or at least 10,000-fold relative to those of untreated cells. In other embodiments, the amount of sialidase protein(s) may be reduced by at least 2-fold, at least 5-fold, at least 10-fold, at least 100-fold, at least 1000-fold, or at least 10,000-fold relative to that of untreated cells. Furthermore, sialidase enzyme activity may be decreased by between 20% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 100% of the value in untreated cells.

#### **(c) preferred embodiments**

**[0037]** Preferably, the cell line comprising disrupted sialidase expression is derived from a CHO cell line. In one embodiment, the CHO cell line comprises disrupted expression of the sialidase consisting of SEQ ID NO:2. In another embodiment, the CHO cell line comprises disrupted expression of the sialidase consisting of SEQ ID NO:4. In still another embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:2 and SEQ ID NO:4. In a further embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:2 and SEQ ID NO:5. In yet another embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:4 and SEQ ID NO:5. In another alternate embodiment, the CHO cell line comprises disrupted

expression of the sialidases consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5. Preferably, sialidase expression is disrupted via RNAi.

### (III) Methods for Producing Glycoproteins With Enhanced Sialylation

**[0038]** Still another aspect of the invention provides a method for producing a glycoprotein comprising enhanced sialylation. In general, the method comprises expressing a nucleic acid sequence encoding the glycoprotein of interest in a cell comprising disrupted expression of at least one nucleic acid sequence encoding a non-cytoplasmic sialidase, wherein the glycoprotein produced by the cells has increased sialylation. In other embodiments, the cell further comprises disrupted expression of a nucleic acid encoding a cytoplasmic sialidase. Sialidase-disrupted cells suitable for use in the method of the invention are described above in Section (II).

**[0039]** The glycoprotein produced by a cell with disrupted sialidase expression generally will have higher levels of sialylation than a glycoprotein produced by a control cell in which the expression of a sialidase has not been altered (e.g., the parental cells from which the sialidase-disrupted cells are derived). The sialylation of the glycoprotein produced by the cell with disrupted sialidase(s) expression may at least about 10% greater than that of a glycoprotein produced by a control cell. In some embodiments, the sialylation of the glycoprotein produced by the cell with disrupted sialidase expression may about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500% greater than that of a glycoprotein produced by control cell. In other embodiments, the sialylation of the glycoprotein produced by the cell with disrupted sialidase expression may be more than about 500% greater than that of a glycoprotein produced by a control cell.

**[0040]** In some embodiments, the sialidase-disrupted cell used for producing the glycoprotein may already express the glycoprotein of interest. For example, the glycoprotein may be endogenous to the cell, whereby the nucleic acid encoding the glycoprotein is present in the genome of the cell. Alternatively, the glycoprotein may be an exogenous to the cell and the acid sequence encoding the glycoprotein may have been stably integrated into a chromosome of the cell. As mentioned above in Section (II)(a), there are commercially available cell lines that express exogenous glycoproteins. For example, the CHO cell line, CHO-hIFN $\gamma$ , stably expresses human interferon gamma.

**[0041]** In other embodiments, the sialidase-disrupted cell used for producing the glycoprotein may not express the glycoprotein of interest. In such instances, the nucleic acid sequence encoding the glycoprotein of interest may be introduced into the sialidase-disrupted cell. The nucleic acid sequence encoding the glycoprotein of interest may be stably integrated into the genome of the sialidase-disrupted cell. Alternatively, nucleic acid sequence encoding the glycoprotein of interest may be transiently introduced in the sialidase-disrupted. Stated another way, the nucleic acid sequence encoding the glycoprotein of interest may be extrachromosomal. Those of skill in the art are familiar with suitable vectors and methods of introducing nucleic acids into cells. Furthermore, guidance may be found in Ausubel et al., *supra* or Sambrook & Russell, *supra*.

**[0042]** Examples of glycoproteins that may be produced by the sialidase-disrupted cells include growth factors, growth factor receptors, cytokines, interleukins and other immune system proteins, interferons, erythropoietin, integrins, adrenergins, selectins, homing receptors, T cell receptors, immunoglobulins, monoclonal antibodies, soluble major histocompatibility complex antigens, enzymes (e.g., tissue plasminogen activator, streptokinase, cholesterol biosynthetic or degradative enzymes, steroidogenic enzymes, kinases, phosphodiesterases, phosphatases, methylases, de-methylases, dehydrogenases, cellulases, proteases, lipases, phospholipases, aromatases, cytochromes, etc.), hormone or peptide receptors, binding proteins, transcription factors, translation factors, oncoproteins or proto-oncoproteins, muscle proteins, myeloproteins, neuroactive proteins, tumor growth suppressing proteins, anti-sepsis proteins, structural proteins, and blood proteins (e.g., thrombin, serum albumin, Factor VII, Factor VIII, Factor IX, Factor X, Protein C, von Willebrand factor, etc.). In some embodiment, the glycoprotein may comprise a peptide tag, such as an antibody epitope tag (e.g., FLAG tag, HA tag, myc tag, 6xHis tag, etc.) In other embodiments, the glycoprotein may be a fusion protein comprising a first domain from a glycoprotein of interest and a second domain from another protein of interest, wherein the two domains either are fused together or separated by one or more additional domains. For example, the first domain may comprise an immunoglobulin domain or portion thereof and the second domain may comprise a non-immunoglobulin polypeptide. The polypeptide or portion thereof may be a naturally occurring polypeptide, it may be an engineered or altered form of a naturally occurring polypeptide, or it may be an artificial or man-made polypeptide.

**[0043]** The method further comprises culturing the sialidase-disrupted cells under conditions whereby the glycoprotein is produced. Those of skill in the art will know the appropriate conditions under which to culture a particular type of cells. In some embodiments, the cells may be grown in small vessels for the production of small amounts of the glycoprotein (e.g., milligrams to grams). In other embodiments, the cells may be maintained in a large bioreactor for the production of large quantities of the glycoprotein (e.g., kilogram quantities). In general, the glycoprotein produced by the sialidase-disrupted cells will have enhanced sialylation relative to the same glycoprotein produced by the same type of cells in which sialidase expression was not disrupted. The amount of sialic acid conjugated to the glycoprotein of interest may be measured by one of several assays known in the art, or with a commercially available kit.



**[0044]** After a period of time, the cells and/or the culture medium will generally be harvested and the glycoprotein of interest may be purified therefrom. Suitable purification methods include affinity chromatography, immunoaffinity chromatography, hydrophobic interaction chromatography, ion exchange chromatography, size exclusion chromatography, precipitation, dialysis, and combinations thereof. See, for example, Roe (ed), Protein Purification Techniques: A Practical Approach, Oxford University Press, 2nd edition, 2001. A skilled artisan will be able to select methods appropriate for a particular glycoprotein of interest.

#### **(IV) Kits**

**[0045]** Still another aspect of the invention encompasses kits for producing glycoproteins comprising enhanced sialylation. Typically, a kit comprises a cell line of the invention, wherein the cell line comprises disrupted expression of at least one non-cytoplasmic sialidase. In some embodiments, the cell line may further comprise disrupted expression of the cytoplasmic sialidase. Sialidase-disrupted cells suitable for use in the kits of the invention are described above in Section (II). The kits may also comprise instructions for use.

**[0046]** In one embodiment, the kit may further comprise suitable culture media for growing the sialidase-disrupted cells. In another embodiment, the kit may further comprise constructs (e.g., plasmid, viral, etc.) for introducing a nucleic acid sequence encoding the glycoprotein of interest into the sialidase-disrupted cells. In still another embodiment, the kit may also further comprise reagents for detecting and/or purifying the glycoprotein that is produced by the cells of the invention. Non-limiting examples of suitable reagents include PCR primers, polyclonal antibodies, monoclonal antibodies, affinity chromatography media, immunoaffinity chromatography media, and the like.

**[0047]** In a preferred embodiment, the kit comprises a CHO cell line comprising disrupted sialidase expression. In one embodiment, the CHO cell line comprises disrupted expression of the sialidase consisting of SEQ ID NO:2. In another embodiment, the CHO cell line comprises disrupted expression of the sialidase consisting of SEQ ID NO:4. In still another embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:2 and SEQ ID NO:4. In a further embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:2 and SEQ ID NO:5. In yet another embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:4 and SEQ ID NO:5. In another alternate embodiment, the CHO cell line comprises disrupted expression of the sialidases consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5. Preferably, sialidase expression is disrupted via RNAi.

#### **DEFINITIONS**

**[0048]** To facilitate understanding of the invention, several terms are defined below.

**[0049]** As used herein, the term "complementary" refers to the association of double-stranded nucleic acids by base pairing through specific hydrogen bonds (i.e., 5'-A G T C-3' pairs with the complementary sequence 3'-T C A G-5'). Two single-stranded molecules may be completely complementary, i.e., all the base pairs are complementary and there are no mismatches. Alternatively, two single-stranded molecules may be substantially complementary, i.e., at least one mismatch exists between the two stands.

**[0050]** The phrase "disrupted expression," as used herein, refers to manipulation of a nucleic acid sequence that codes for a polypeptide such that the polypeptide is not made (i.e., knocked out) or the polypeptide is made at reduced levels (i.e., knocked down). Expression may be disrupted at several levels. For example, the DNA encoding the polypeptide may be altered such that no functional messenger RNA, and hence, no functional protein is made. Alternatively, the messenger RNA may be affected such that none of the polypeptide is made or the polypeptide is made at reduced levels.

**[0051]** The term "hybridization," as used herein, refers to the process of hydrogen bonding, or base pairing, between the bases comprising two complementary single-stranded nucleic acid molecules to form a double-stranded hybrid or duplex. The "stringency" of hybridization is typically determined by the conditions of temperature and ionic strength. Nucleic acid hybrid stability is generally expressed as the melting temperature or  $T_m$ , which is the temperature at which the hybrid is 50% denatured under defined conditions. Equations have been derived to estimate the  $T_m$  of a given hybrid; the equations take into account the G+C content of the nucleic acid, the nature of the hybrid (e.g., DNA:DNA, DNA:RNA, etc.), the length of the nucleic acid probe, etc. (see for example, Sambrook and Russell, *supra*). One skilled in the art will appreciate which parameters to manipulate to optimize hybridization during hybridization-based reactions. In some hybridization-based reactions, however, such as polymerase reactions, amplification reactions, etc., the temperature of the reaction typically determines the stringency of the hybridization. Furthermore, the temperature also typically determines the stringency of the hybridization during *in vivo* reactions.

**[0052]** As used herein, the terms "identity" or "identical" refers to the extent that two nucleotide sequence or two amino acid sequences are the same when aligned for maximum correspondence. Optimal alignment and the percent identity between nucleotide sequences may be determined using the BLASTN algorithm of Altschul et al. (J. Mol. Biol. 215:403-410, 1990), and optimal alignment and the percent identity between two amino acid sequences may be deter-

mined using the BLASTP algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268, 1993). These algorithms are incorporated into the BLAST programs at the NCBI website (<http://www.ncbi.nlm.nih.gov/BLAST/>). To obtain gapped alignments for comparison purposes, Gapped BLAST may be utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs are employed. The percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which an identical nucleotide occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

**[0053]** The term "nucleic acid" refers to molecules comprising deoxyribonucleotides or ribonucleotides. The nucleotides may be standard nucleotides (i.e., adenosine, guanosine, cytidine, thymidine, and uridine) or nucleotide analogs. A nucleotide analog refers to a nucleotide having a modified purine or pyrimidine base or a modified ribose moiety. A nucleotide analog may be a naturally occurring nucleotide (e.g., inosine) or a non-naturally occurring nucleotide. Non-limiting examples of modifications on the sugar or base moieties of a nucleotide include the addition (or removal) of acetyl groups, amino groups, carboxyl groups, carboxymethyl groups, hydroxyl groups, methyl groups, phosphoryl groups, and thiol groups, as well as the substitution of the carbon and nitrogen atoms of the bases with other atoms (e.g., 7-deaza purines). Nucleotide analogs also include dideoxy nucleotides, 2'-O-methyl nucleotides, locked nucleic acids (LNA), peptide nucleic acids (PNA), and morpholinos. The nucleotides may be linked by phosphodiester, phosphothioate, phosphoramidite, or phosphorodiamidate bonds.

**[0054]** "Sialidases" are a group of enzymes that catalyze the hydrolysis of terminal sialic acid residues from glycoconjugates, such as glycoproteins. Sialidases are also referred to as  $\alpha$ -sialidases, neuraminidases, or acetylneuraminidases.

**[0055]** When introducing elements of the present invention or the preferred embodiments(s) thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

**[0056]** Having described the invention in detail, it will be apparent that modifications and variations are possible without departing from the scope of the invention defined in the appended claims.

## EXAMPLES

**[0057]** The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors to function well in the practice of the invention. Those of skill in the art should, however, in light of the present disclosure, appreciate that many changes could be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention, therefore all matter set forth is to be interpreted as illustrative and not in a limiting sense.

### Example 1. Isolation of Additional Sialidase Genes in CHO Cells.

**[0058]** Four sialidase genes (Neu1, Neu2, Neu3, and Neu4) have been identified and well-characterized in human, mouse, and rat. These sialidases exhibit different enzyme activities, substrate preferences, and subcellular locations. To date, however, only one sialidase gene has been characterized in CHO cells. This gene encodes a cytoplasmic sialidase (i.e., Neu2) (Gramer MJ, Goochee CF. (1993) Biotechnol Prog, 9: 366). The purpose of this study was to determine whether CHO cells contain the other sialidase genes.

**[0059]** Using RT-PCR, 5'/3' RACE (rapid amplification of cDNA ends), and other standard methods, the other three sialidase genes were isolated and cloned from CHO cells. CHO Neu1 encoded a protein with 410 amino acid residues, and CHO Neu3 encoded a protein with 417 amino acid residues (Table 1). On the other hand, CHO Neu4 appeared to be a pseudogene in CHO cells. Both of Neu1 and Neu3 shared high similarities with their counterparts in other species (Table 2).

**Table 1.** Characteristics of New Sialidases in CHO Cells

	cDNA	SEQ ID NO:	protein	SEQ ID NO:
Neu1	1463 bp	1	410 aa	2
Neu3	1833 bp	3	417 aa	4

**Table 2.** Percent Similarity Between Sialidase Proteins.

CHO Sialidases	Human Sialidases	Mouse Sialidases	Rat Sialidases
Neu1 (SEQ ID NO:2)	86.5%	95.4%	95.6%
Neu2 (SEQ ID NO:5)	77.1%	86.5%	87.1%
Neu3 (SEQ ID NO:4)	76.8%	81.1%	83.3%

**Example 2. CHO Neu1 and CHO Neu3 are Sialidases.**

**[0060]** Enzymatic sialidase activity studies were performed to confirm that the proteins coded by these two new genes having the expected functions in CHO cells. Briefly, the coding regions for the Neu1 (SEQ ID NO:1) and Neu3 (SEQ ID NO:3) genes, as well as the coding region of the previously reported Neu2 gene (Ferrari et al. (1994) Glycobiology 4(3):367-373) were cloned into pcDNA3.1 mammalian expression vectors. The expression constructs then were transfected into COS7 cells to overexpress the sialidase proteins. The pcDNA3.1 vector alone was also transfected into COS7 cells as the mock transfection. An expression construct containing green fluorescence protein (GFP) was cotransfected into the COS7 cells to normalize the transfection efficiency.

**[0061]** Twenty-four hours after transfection, the cells were lysed by sonication. The cell debris was removed by centrifugation at 1000 x g for 10 min at 4°C and the supernatant fractions were collected for enzymatic activity. The sialidase assay was performed as previously described (Gramer et al. (1993) Biotechnol Prog 9: 366-373) using 1 mM of 4-methylumbelliferone-Neu5Ac as substrate. For each lysate, 100 µg of protein was used in the assay. The assay was performed in triplicate. After normalization with the GFP readings, the CHO Neu1 and Neu3 proteins had significant sialidase activities (Figure 1) as compared to the negative control (mock transfection) and the positive control (Neu2). In fact, the Neu3 protein had more than approximately 6-15 times as much activity as Neu2.

**[0062]** To further examine the activity of these sialidase proteins, the sialidase assay was performed in the presence of two different sialidase inhibitors (Neu5Ac and Neu5Ac2en) at two concentrations. As shown in Figure 2, Neu5Ac2en had greater inhibitory effects than Neu5Ac on all the sialidases. Using CHO Neu3 as an example, 0.1 mM Neu3Ac2en decreased the activity about 30% and 0.5 mM Neu3Ac2en reduced the activity about 60%. These data indicate that the newly identified CHO genes (Neu1, and Neu3) code for sialidases.

**Example 3. Subcellular Localization of CHO Sialidases.**

**[0063]** To identify the subcellular location for the two new CHO sialidases, immunocytochemistry with Confocal Scanning Microscopy technology was performed. Briefly, the Flag-tag encoding 8 amino acid residues (DYKDDDDK) was cloned into the 3'-end of Neu expression constructs to express Flag-tagged fusion proteins. The Flag-tagged constructs were transfected into COS7 cells. Twenty-four hours after transfection, the cells were immunostained using standard procedures.

**[0064]** The results are presented in Figure 3. The subcellular locations of the sialidases are indicated by the green fluorescence generated by the FITC-conjugated anti-FLAG antibody. The transfected cells were also immunostained with organelle markers: a lysosomal marker (LysoTracker DND-99), which is indicated by the red fluorescence and a plasma membrane marker (wheat germ agglutinin 647), which is indicated by the blue signal in the Figure 3. This study revealed that Neu1 localized to lysosomes; its pattern of stain was nearly identical to that of the lysosomal marker. Neu3 localized to the plasma membrane, in a manner similar to that of the plasma membrane marker. Further, Neu2, the positive control, displayed cytoplasmic staining, as expected.

**Example 4. Gene Silencing Using siRNA Technology.**

**[0065]** The expression of each of the three CHO sialidase genes was knocked down using small interfering RNA (siRNA) technologies. Based on the cDNA sequences, several siRNAs against the CHO sialidase genes (Neu1, Neu2, and Neu3) were designed and synthesized for each gene. The sequences are presented in Table 3. These siRNAs were transfected into a CHO cell line stably expressing human interferon gamma (CHO-hIFN $\gamma$ ). The transfections were performed in duplicate. Forty-eight hours after transfection, the cells were harvested. RNA and protein were isolated from the transfected cells. Reverse transcription polymerase chain reaction, (RT-PCR) and quantitative RT-PCR (Q-RT-PCR) using gene-specific primers were performed using standard procedures.

Table 3. siRNA Sequences.			
Gene	siRNA	Nucleotide sequence (5'-3')*	SEQ ID NO
Neu1	S2-sense	GGGUGCAAGACGACUUCAGtt	6
	S2-antisense	CUGAAGUCGUCUUGCACCCtt	7
	S3-sense	UGGGACGCGUGGAACGAGAUtt	8
	S3-antisense	AUCUCGUUCCAGCGUCCCAtt	9
	S4-sense	GGACACUACGCGUCAUCUGtt	10
	S4-antisense	CAGAUGACGCGUAGUGUCtt	11
Neu2	S2-sense	CCUGGGUGUGUACCUCAAUtt	12
	S2-antisense	AUUGAGGUACACACCCAGGtt	13
	S3-sense	GACGGAUGAGCAUGCAGAUtt	14
	S3-antisense	AUCUGCAUGCUCAUCCGUCtt	15
Neu3	S1-sense	GGGACCACCUACCGGAUUCtt	16
	S1-antisense	GAAUCCGGUAGGUGGUCCtt	17
	S2-sense	GUACCAGCCGUGUGUUACUtt	18
	S2-antisense	AGUAACACACGGCUGGUACtt	19
* Upper case letters denote the 19 nt siRNA sequence and lower case letters denote the 3' overhang.			

**[0066]** As shown in Figure 4, RT-PCR analysis showed that at least two of each set of siRNAs were able to reduce the mRNA expression of each gene. Neu1-S2, Neu1-S3, and Neu1-S4 reduced the expression of Neu1 mRNA, Neu2-S2 and Neu2-S3 reduced the expression of Neu2 mRNA, and Neu3-S1 and Neu3-S2 reduced the expression of Neu3 mRNA. Quantitative-reverse transcriptase (Q-RT) PCR analysis indicated that siRNAs against CHO sialidase genes significantly reduced mRNA expression levels (i.e., ~ 70% - 95%) compared to a control siRNA targeting an unrelated nucleic acid sequence (the GFP nucleic acid sequence) (Figure 5). Neu1 mRNA expression was reduced approximately 90% (Figure 5A); Neu2 mRNA expression was reduced about 70-85% (Figure 5B); and Neu3 mRNA expression was reduced about 95% (Figure 5C).

**[0067]** To further confirm the gene silencing effects at the protein level, a sialidase activity assay was performed. Adherent CHO-hIFN $\gamma$  cells were suspended into a chemically defined and animal-component free medium. Positive siRNAs identified above were transfected by electroporation, in duplicate, into the suspension of CHO-hIFN $\gamma$  cells. To investigate the potential synergistic gene silencing effects, each Neu gene was silenced individually and in combination (i.e., two or three genes were silenced). Seventy-two hours after transfection, the cells were harvested and washed with pre-chilled 1X PBS buffer. Total RNA and protein were separately isolated from the siRNA-transfected cells. Total RNA was used for reverse transcription (and Q-RT PCR) as described above. Protein was used for *in vitro* sialidase activity assays, as detailed in Example 2. Individual siRNA and siRNA combinations all significantly reduced the sialidase enzymatic activity compared to the controls (parental CHO-hIFN $\gamma$  cells and GFP siRNA transfected cells) (Figure 6). Most interestingly, the combination of siRNAs against Neu1 and Neu3 dramatically reduced sialidase activity to an undetectable level.

#### Example 5. Stable Gene Silencing Using shRNA Technology.

**[0068]** Based on the results in Example 4 showing that Neu mRNA and sialidase activity could be knocked down using siRNAs, Neu gene expression was stably knocked down in CHO hIFN $\gamma$  cells using a shRNA technology platform (Mission: RNAi™, Sigma Aldrich, St. Louis, MO).

**[0069]** DNA fragments encoding the effective siRNAs for each sialidase gene (Neu1-S4, Neu2-S3, Neu3-S2) were cloned into the pLKO.1-puro shRNA expression vector. After DNA sequencing confirmation, plasmid DNAs were transfected into HEK293 cells to produce lentivirus packed with shRNA cassettes. After infection of suspension CHO-hIFN $\gamma$  cells with lentivirus containing shRNA cassettes and puromycin selection, CHO-hIFN $\gamma$  cells harboring shRNA cassettes for Neu1, Neu2 and Neu3 genes were obtained. Q-RT PCR was performed to confirm gene-silencing effects at the level of mRNA (Figure 7). The mRNA expression knockdown of Neu1 (Neu1-S4) was over 95% in Neu1-shRNA cells (Figure

7A), about 50% knockdown with Neu2 (Neu2-S3) in Neu2-shRNA cells (Figure 7B), and over 70% knockdown with Neu3 (Neu3-S2) in Neu3-shRNA cells (Figure 7C).

[0070] Gene knockdown effects were also confirmed at the protein level by measuring sialidase activity as detailed above. Compared to the control (non-target shRNA), the shRNAs against all three sialidase genes significantly reduced the sialidase activity in CHO-hIFN $\gamma$  cells (see Figure 8). The cells harboring Neu3-S2 shRNA had the most dramatic reduction in sialidase activity.

[0071] To evaluate whether shRNAs affected cell growth and/or protein production, the growth of these CHO-shRNA cells and their production of human interferon gamma protein were analyzed. Briefly, cells were inoculated at ~ 200,000 cells/ml viable cell density in the culture medium (chemically defined and animal-component free) supplemented with 4 mM glutamine. The cell growth assay was set up in duplicate. Cells were cultured in 5L bioreactors at 37°C, with 5% CO<sub>2</sub>. At appropriate time points, samples of media were collected for protein analysis.

[0072] The 5L bioreactor cell growth data indicated that none of the shRNAs negatively affected cell growth as compared to the non-target shRNA control cells (Figure 9). Production of human IFN $\gamma$  was measured using an ELISA kit for human IFN $\gamma$  (eBioscience, San Diego, CA). As shown in Figure 10, none of the shRNAs negatively affected protein production as compared to the nontarget control cells. In fact, higher levels of human IFN $\gamma$  protein were produced by some of the sialidase shRNA targeted cells. Similar results were obtained using 250-ml shaker flasks (data not shown).

#### Example 6. Silencing of CHO Neu Genes Produces Glycoproteins With Increased Sialic Acid Content.

[0073] The levels of sialic acid were analyzed by HPLC in human IFN $\gamma$  protein produced by the sialidase shRNA targeted cells and non-target shRNA control cells. Spent media samples were collected from 5L bioreactor cultures at stationary phase (day 6, cell viability around 95%) and death phase (day 13, cell viability around 20%). Human interferon gamma proteins were purified from cell culture supernatants by immunoaffinity purification. Briefly, after centrifugation and filtration to remove cell debris, 30 ml of a protein sample was loaded on an affinity column conjugated with hIFN $\gamma$  antibody. After washing the column, hIFN $\gamma$  protein was eluted with elution buffer. Purification was carried out on an AKTA Explorer 100 chromatographic system (Amersham Biosciences). The purified protein was quantified by ELISA as previously described.

[0074] The sialylation of purified hIFN $\gamma$  proteins were analyzed by HPLC. Briefly, 50  $\mu$ g of purified hIFN $\gamma$  protein sample was lyophilized and resuspended in 100  $\mu$ l of ultrapure water with 2N acetic acid. The sample was hydrolyzed at 80°C for 3 hours. Then the sample was filtered and speed-vac dried. Released sialic acid residues were derivatized with a fluorogenic compound, 1,2-diamino-4,5-(methylenedioxy)benzene (DMB), followed by HPLC using C18 reverse phase column.

[0075] The data are presented in Figure 11. On day 6, the levels of sialic acid in hIFN $\gamma$  protein produced by Neu1 and Neu2 shRNA CHO cells were not significantly different from non-target shRNA control (Fig. 11A). Although the level of sialic acid appeared to be slightly higher in Neu2 shRNA cells, it was not significant (Neu2:  $1.945 \pm 0.111$  pmol sialic acid/pmol hIFN $\gamma$  vs. non-target:  $1.600 \pm 0.090$  pmol sialic acid/pmol hIFN $\gamma$ ,  $p = 0.0528$ ,  $n=4$ ). However, the sialic acid content of hIFN $\gamma$  protein from Neu3 shRNA CHO cells was increased significantly comparing to protein from control cells (Neu3:  $2.133 \pm 0.101$  pmol sialic acid/pmol hIFN $\gamma$  vs. non-target:  $1.600 \pm 0.090$  pmol sialic acid/pmol hIFN $\gamma$ ,  $p < 0.01$ ,  $n = 4$ ).

[0076] On day 13, there was no obvious improvement of sialylation with hIFN $\gamma$  produced from Neu1 shRNA CHO cells. However, the levels of sialic acid were enhanced in hIFN $\gamma$  protein produced by Neu2 cells (Neu2:  $4.948 \pm 0.150$  pmol sialic acid/pmol hIFN $\gamma$  vs. non-target:  $4.113 \pm 0.113$  pmol sialic acid/pmol hIFN $\gamma$ ,  $p < 0.01$ ,  $n=4$ ) and Neu3 cells (Neu3:  $5.175 \pm 0.414$  pmol sialic acid/pmol hIFN $\gamma$  vs. non-target:  $4.113 \pm 0.113$  pmol sialic acid/pmol hIFN $\gamma$ ,  $p < 0.05$ ,  $n=4$ ) (Fig. 11 B). The sialylation enhancement of human interferon gamma protein produced from Neu3 and Neu2 shRNA CHO cells indicates that the down-regulation of sialidase genes (Neu3 and Neu2) reduced overall sialidase activity and consequently reduced the levels of sialic acid in recombinant proteins produced by CHO cells. These examples demonstrate that targeted gene silencing using an RNA interference platform is an efficient way to improve protein glycosylation.

# EP 2 930 245 A1

## SEQUENCE LISTING

<110> SIGMA-ALDRICH CO.  
 ZHANG, Min  
 ROSS, James  
 <120> CELL LINE AND METHODS FOR IMPROVED GLYCOPROTEIN SIALYLATION  
 <130> P1764EP01  
 <140> PCT/US2008/079695  
 <141> 2008-10-13  
 <150> US 60/979,483  
 <151> 2007-10-12  
 <160> 19  
 <170> PatentIn version 3.5  
 <210> 1  
 <211> 1463  
 <212> DNA  
 <213> Cricetulus griseus  
 <400> 1  
 ggggcgagca atggtggcgg cagcacagcc gagcagaccc cggggggccgc cgagcggctg 60  
 ggcgagccgt cgggggtcagg tgctcgcagc gctcttcctg ctgctggcgt ccgtggcggg 120  
 atccgaggcc aggggtgcaag acgacttcag tctggtgcag ccgctggtga ccatggagca 180  
 gctgctgtgg gtgagcggga ggcagatcgg ctcggtggac actttccgca tcccgtcat 240  
 caccgccacc cctcggggca cgctcctcgc cttcgcgcag gccaggaaaa cgtctgcctc 300  
 cgatgagggg gccaaagttca tcgccatgag gaggtccacg gaccagggtg gtacatggtc 360  
 ctgcagaccc ttcatcgtag acgatgggga ggcctccgac gggctgaacc tggggggcgt 420  
 ggtgaacgac gtggacacag ggggtggtgtt ccttatctat accctgtgtg ctcacaaggt 480  
 caactgccag gtggcctcca ccatgttggt gtggagtaaa gacgatggca tttcctggag 540  
 cccaccccg g aatctctccg tggacattgg cacagaaatg tttgcccctg gaccaggctc 600  
 tggcattcag aaacagcggg agcctcggaa gggccggctc attgtgtgtg gccatgggac 660  
 gctggaacga gatggagtct tttgtctcct cagtgatgac cacgggtgcct cgtggcacta 720  
 cgggactgga gtgagcggca ttcccttcgg ccagcccaaa cacgagcacg atttcaaccc 780  
 cgacgagtgc cagccctacg agcttccaga tggctctgtc atcatcaatg cccggaacca 840  
 gaacaactac cattgccgct gcaggatcgt cctccgcagc tatgatgcct gcgataccct 900  
 caggccccgg gatgtaacct tcgacccga gctggtggac cctgtggtag cagcaggagc 960  
 attagccacc agctcaggca ttgtcttctt ctccaatcca gccatcctg agttccgagt 1020  
 gaacctgacc ctgcgctgga gcttcagcaa cggtagctcc tggcagaagg agagagtcca 1080  
 ggtgtggccg ggacccagcg gctactcgtc cctgactgcc ctggaaaaca gcacggaggg 1140

EP 2 930 245 A1

agagcagcag cccccgcagc tgttcgttct gtacgagaag ggcctgaacc agtacaccga 1200  
gagcatctcc atggtgaaaa tcagtgtcta cggcacgctc tgagccccac cggcgcccaa 1260  
5 ggacactacg cgtcatctga cctcacggct ctctcgaggg gctgcagaaa gggcctgaag 1320  
cacagctctt cctcgggatg ctagcctttt gcagagcagt ttctctttaa caggggaagcc 1380  
actccgttag gacctaacag ctgccagct gcctctccca gacaggaagt tcctccctca 1440  
10 ccaagagcac tttgtagaag gct 1463

<210> 2  
<211> 410  
15 <212> PRT  
<213> Cricetulus griseus  
<400> 2

Met Val Ala Ala Ala Gln Pro Ser Arg Pro Arg Gly Pro Pro Ser Gly  
20 1 5 10 15

Trp Ala Ser Arg Arg Gly Gln Val Leu Ala Ala Leu Phe Leu Leu Leu  
25 20 25 30

Ala Ser Val Ala Gly Ser Glu Ala Arg Val Gln Asp Asp Phe Ser Leu  
35 35 40 45

Val Gln Pro Leu Val Thr Met Glu Gln Leu Leu Trp Val Ser Gly Arg  
40 50 55 60

Gln Ile Gly Ser Val Asp Thr Phe Arg Ile Pro Leu Ile Thr Ala Thr  
45 65 70 75 80

Pro Arg Gly Thr Leu Leu Ala Phe Ala Glu Ala Arg Lys Thr Ser Ala  
50 85 90 95

Ser Asp Glu Gly Ala Lys Phe Ile Ala Met Arg Arg Ser Thr Asp Gln  
55 100 105 110

Gly Ser Thr Trp Ser Ser Thr Ala Phe Ile Val Asp Asp Gly Glu Ala  
60 115 120 125

Ser Asp Gly Leu Asn Leu Gly Ala Val Val Asn Asp Val Asp Thr Gly  
65 130 135 140

Val Val Phe Leu Ile Tyr Thr Leu Cys Ala His Lys Val Asn Cys Gln  
70 145 150 155 160

Val Ala Ser Thr Met Leu Val Trp Ser Lys Asp Asp Gly Ile Ser Trp  
75 165 170 175

# EP 2 930 245 A1

	Ser	Pro	Pro	Arg	Asn	Leu	Ser	Val	Asp	Ile	Gly	Thr	Glu	Met	Phe	Ala	
				180					185					190			
5	Pro	Gly	Pro	Gly	Ser	Gly	Ile	Gln	Lys	Gln	Arg	Glu	Pro	Arg	Lys	Gly	
			195					200					205				
10	Arg	Leu	Ile	Val	Cys	Gly	His	Gly	Thr	Leu	Glu	Arg	Asp	Gly	Val	Phe	
		210					215					220					
15	Cys	Leu	Leu	Ser	Asp	Asp	His	Gly	Ala	Ser	Trp	His	Tyr	Gly	Thr	Gly	
	225					230					235					240	
20	Val	Ser	Gly	Ile	Pro	Phe	Gly	Gln	Pro	Lys	His	Glu	His	Asp	Phe	Asn	
					245					250					255		
25	Pro	Asp	Glu	Cys	Gln	Pro	Tyr	Glu	Leu	Pro	Asp	Gly	Ser	Val	Ile	Ile	
				260					265					270			
30	Asn	Ala	Arg	Asn	Gln	Asn	Asn	Tyr	His	Cys	Arg	Cys	Arg	Ile	Val	Leu	
			275					280					285				
35	Arg	Ser	Tyr	Asp	Ala	Cys	Asp	Thr	Leu	Arg	Pro	Arg	Asp	Val	Thr	Phe	
		290					295					300					
40	Asp	Pro	Glu	Leu	Val	Asp	Pro	Val	Val	Ala	Ala	Gly	Ala	Leu	Ala	Thr	
	305					310					315					320	
45	Ser	Ser	Gly	Ile	Val	Phe	Phe	Ser	Asn	Pro	Ala	His	Pro	Glu	Phe	Arg	
					325					330					335		
50	Val	Asn	Leu	Thr	Leu	Arg	Trp	Ser	Phe	Ser	Asn	Gly	Thr	Ser	Trp	Gln	
				340					345					350			
55	Lys	Glu	Arg	Val	Gln	Val	Trp	Pro	Gly	Pro	Ser	Gly	Tyr	Ser	Ser	Leu	
			355					360					365				
60	Thr	Ala	Leu	Glu	Asn	Ser	Thr	Glu	Gly	Glu	Gln	Gln	Pro	Pro	Gln	Leu	
		370					375					380					
65	Phe	Val	Leu	Tyr	Glu	Lys	Gly	Leu	Asn	Gln	Tyr	Thr	Glu	Ser	Ile	Ser	
	385					390					395					400	
70	Met	Val	Lys	Ile	Ser	Val	Tyr	Gly	Thr	Leu							
					405					410							
75	<210>																3



# EP 2 930 245 A1

<211> 1833  
<212> DNA  
<213> *Cricetulus griseus*

5 <400> 3  
gcgcgtgggc gtggcgtcac ttcagcacgg cgcggtctct ctttcctgcc agctcctgct 60  
cagagttgtc aggggtctgtc tccgcgtcag tggtttccgt ctccgcttcc ctgcctccat 120  
10 cgtcccagcc cttctgcagg tcctcctccg agacctcaag gagagctcag aagccagaga 180  
cactagagcc gaagtcattg aagaagtatc agcctgctcc ctcaacagca ctctgttcca 240  
gcaggaacac cagaaaggga ccacctaccg gattccagcg ctgctctaca tccctcccag 300  
15 ccacaccttc ctggcctttg cagagaagcg ttcctcaagc aaagacgtag atgctctcca 360  
cctggtgctc aggcgagggg tgatgaaggg ccactctgta gagggggac ccctgcagcc 420  
actgatggaa gccacattgc ctgggcatcg gacctgaac ccctgccctg tatgggagca 480  
20 gaggaccagc cgtgtgttac tgtttttcat ctgtgtgcca gaccgtgtta ctgaacattg 540  
gcagattagg tcaggcaaga atgccgcccg tctctgcttc ctgtgcagtc aggatgctgg 600  
gtgctcatgg ggtgaagtga aggacttgac tgaggaggtc attggctcag agttgaagca 660  
25 ctggggccaca tttgctgtgg gcccaggcca tggcatccgg ctgcagtcag gaaggctgat 720  
cattcccacc tacgcctact atttctcatg caggttcctc tgcttcccgt gttcagtcaa 780  
gccccattcc ctgatgatct acagtgatga cttaggagtc acatggcacc atggcaagct 840  
30 cattggggcc cagggtgacag gggagtgcca agtggcagaa gtgactggga cgtctggtaa 900  
ccttgtgctc tactgcaatg cccggacacc aaacagattc cgagcagaat cttttagtag 960  
35 tgattacggt gactgttttc agaaaccaac cctgaacaca caactctgtg agccccgcta 1020  
tggtctgcaa ggcagtatag tgagcttcca gcccttgaag atgccattct cacaagaccc 1080  
aattggtaaa gctgctccca ctactcagaa gagccctctg ctggacagtt ttctggagcg 1140  
40 ggaggaagga gttggaagac catcaggaac atggctcttg tactcacatc caactagcaa 1200  
gaagcggaga attaacctgg gcatctacta caaccggaac cccttgaggg tgacctgctg 1260  
gtcccgccct tggatcttgc actgtgggcc ctgtggctac tctgatctgg ctgttgtgga 1320  
45 agagcagggc ttatttgcatt gtttgtttga atgtgggcag gagcatgagt gtgagcagat 1380  
tgcttccgt ctattttcag tccaagaggt tttgagctgt gaagactgca ctggccctag 1440  
tagggactaa agccaaatca agcccgatgg gtgaggaccc aactttcctc agaagtgaat 1500  
50 tccaagaggt tttgagctgt gaagactgca ctggccctag tagggactaa agccaaatca 1560  
agcccgatgg gtgaggaccc aactttcctc agaagtgaat ccaagagaaa tgtgtgcctt 1620  
atcttacaca gcaataaggg tgttgaactg ggagcttgga gacaatggtg tggttttggc 1680  
55 ttgctttagg actgtggata tatcccctga actctgggca tcaggtctcc atttgtaaaa 1740

EP 2 930 245 A1

tgacaagggg ggtttgtgat ttcttgtctt cccattaaaa ggagtgttca cttcttgtcc 1800  
cacgaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1833

5  
<210> 4  
<211> 417  
<212> PRT  
<213> Cricetulus griseus

10  
<400> 4

Met Glu Glu Val Ser Ala Cys Ser Leu Asn Ser Thr Leu Phe Gln Gln  
1 5 10 15

15  
Glu His Gln Lys Gly Thr Thr Tyr Arg Ile Pro Ala Leu Leu Tyr Ile  
20 25 30

20  
Pro Pro Ser His Thr Phe Leu Ala Phe Ala Glu Lys Arg Ser Ser Ser  
35 40 45

Lys Asp Val Asp Ala Leu His Leu Val Leu Arg Arg Gly Val Met Lys  
50 55 60

25  
Gly His Ser Val Glu Trp Gly Pro Leu Gln Pro Leu Met Glu Ala Thr  
65 70 75 80

30  
Leu Pro Gly His Arg Thr Met Asn Pro Cys Pro Val Trp Glu Gln Ser  
85 90 95

35  
Thr Ser Arg Val Leu Leu Phe Phe Ile Cys Val Pro Asp Arg Val Thr  
100 105 110

Glu His Trp Gln Ile Arg Ser Gly Lys Asn Ala Ala Arg Leu Cys Phe  
115 120 125

40  
Leu Cys Ser Gln Asp Ala Gly Cys Ser Trp Gly Glu Val Lys Asp Leu  
130 135 140

45  
Thr Glu Glu Val Ile Gly Ser Glu Leu Lys His Trp Ala Thr Phe Ala  
145 150 155 160

Val Gly Pro Gly His Gly Ile Arg Leu Gln Ser Gly Arg Leu Ile Ile  
165 170 175

50  
Pro Thr Tyr Ala Tyr Tyr Phe Ser Cys Arg Phe Leu Cys Phe Pro Cys  
180 185 190

55  
Ser Val Lys Pro His Ser Leu Met Ile Tyr Ser Asp Asp Leu Gly Val  
195 200 205

# EP 2 930 245 A1

	Thr	Trp	His	His	Gly	Lys	Leu	Ile	Gly	Pro	Gln	Val	Thr	Gly	Glu	Cys	
	210						215					220					
5	Gln	Val	Ala	Glu	Val	Thr	Gly	Thr	Ser	Gly	Asn	Leu	Val	Leu	Tyr	Cys	
	225					230					235					240	
	Asn	Ala	Arg	Thr	Pro	Asn	Arg	Phe	Arg	Ala	Glu	Ser	Phe	Ser	Thr	Asp	
10					245					250					255		
	Tyr	Gly	Asp	Cys	Phe	Gln	Lys	Pro	Thr	Leu	Asn	Thr	Gln	Leu	Cys	Glu	
				260					265					270			
15	Pro	Arg	Tyr	Gly	Cys	Gln	Gly	Ser	Ile	Val	Ser	Phe	Gln	Pro	Leu	Lys	
			275					280					285				
	Met	Pro	Phe	Ser	Gln	Asp	Pro	Ile	Gly	Lys	Ala	Ala	Pro	Thr	Thr	Gln	
20							290					300					
	Lys	Ser	Pro	Leu	Leu	Asp	Ser	Phe	Leu	Glu	Arg	Glu	Glu	Gly	Val	Gly	
25	305					310					315					320	
	Arg	Pro	Ser	Gly	Thr	Trp	Leu	Leu	Tyr	Ser	His	Pro	Thr	Ser	Lys	Lys	
					325					330					335		
30	Arg	Arg	Ile	Asn	Leu	Gly	Ile	Tyr	Tyr	Asn	Arg	Asn	Pro	Leu	Glu	Val	
				340					345					350			
	Thr	Cys	Trp	Ser	Arg	Pro	Trp	Ile	Leu	His	Cys	Gly	Pro	Cys	Gly	Tyr	
35			355					360					365				
	Ser	Asp	Leu	Ala	Val	Val	Glu	Glu	Gln	Gly	Leu	Phe	Ala	Cys	Leu	Phe	
		370					375					380					
40	Glu	Cys	Gly	Gln	Glu	His	Glu	Cys	Glu	Gln	Ile	Ala	Phe	Arg	Leu	Phe	
	385					390					395					400	
	Ser	Val	Gln	Glu	Val	Leu	Ser	Cys	Glu	Asp	Cys	Thr	Gly	Pro	Ser	Arg	
45					405					410					415		
	Asp																
50																	
	<210> 5																
	<211> 379																
	<212> PRT																
55	<213> Cricetulus griseus																
	<400> 5																

EP 2 930 245 A1

	Met	Ala	Thr	Cys	Pro	Val	Leu	Gln	Lys	Glu	Thr	Leu	Phe	Gln	Thr	Gly	
	1				5					10					15		
5	Asp	Tyr	Ala	Tyr	Arg	Ile	Pro	Ala	Leu	Ile	Tyr	Leu	Ser	Lys	Gln	Lys	
				20					25					30			
	Thr	Leu	Leu	Ala	Phe	Ala	Glu	Lys	Arg	Leu	Thr	Lys	Thr	Asp	Glu	His	
10			35					40					45				
	Ala	Asp	Leu	Phe	Val	Leu	Arg	Arg	Gly	Ser	Tyr	Asn	Ala	Asp	Thr	His	
		50					55					60					
15	Gln	Val	Gln	Trp	Gln	Ala	Glu	Glu	Val	Val	Thr	Gln	Ala	Tyr	Leu	Glu	
	65					70					75					80	
	Gly	His	Arg	Ser	Met	Ser	Pro	Cys	Pro	Leu	Tyr	Asp	Lys	Gln	Thr	Arg	
20					85					90					95		
	Thr	Leu	Phe	Leu	Phe	Phe	Ile	Ala	Val	Arg	Gly	Gln	Ile	Ser	Glu	His	
				100					105					110			
25																	
	His	Gln	Leu	Gln	Thr	Gly	Val	Asn	Val	Thr	Arg	Leu	Cys	His	Ile	Thr	
			115					120					125				
	Ser	Thr	Asp	His	Gly	Lys	Thr	Trp	Ser	Ala	Val	Gln	Asp	Leu	Thr	Asp	
30		130					135					140					
	Thr	Thr	Ile	Gly	Ser	Thr	His	Gln	Asp	Trp	Ala	Thr	Phe	Gly	Val	Gly	
35	145					150					155					160	
	Pro	Gly	His	Cys	Leu	Gln	Leu	Arg	Asn	Thr	Ala	Gly	Ser	Leu	Leu	Val	
					165					170					175		
40																	
	Pro	Ala	Tyr	Ala	Tyr	Arg	Lys	Gln	Pro	Pro	Ile	His	Ala	Pro	Ala	Pro	
				180					185					190			
	Ser	Ala	Phe	Cys	Phe	Leu	Ser	His	Asp	His	Gly	Ser	Thr	Trp	Glu	Leu	
45			195					200					205				
	Gly	His	Phe	Val	Ser	Gln	Asn	Ser	Leu	Glu	Cys	Gln	Val	Ala	Glu	Val	
		210					215					220					
50																	
	Gly	Thr	Gly	Ala	Glu	Arg	Val	Val	Tyr	Leu	Asn	Ala	Arg	Ser	Cys	Leu	
	225					230					235					240	
55	Gly	Ala	Arg	Val	Gln	Ala	Gln	Ser	Pro	Asn	Ser	Gly	Leu	Asp	Phe	Gln	
					245					250					255		

# EP 2 930 245 A1

	Asp	Asn	Gln	Val	Val	Ser	Lys	Leu	Val	Glu	Pro	Pro	Lys	Gly	Cys	His	
				260					265					270			
5	Gly	Ser	Val	Ile	Ala	Phe	Pro	Asn	Pro	Thr	Ser	Lys	Ala	Asp	Ala	Leu	
			275					280					285				
10	Asp	Val	Trp	Leu	Leu	Tyr	Thr	His	Pro	Thr	Asp	Ser	Arg	Lys	Arg	Thr	
		290					295					300					
15	Asn	Leu	Gly	Val	Tyr	Leu	Asn	Gln	Lys	Pro	Leu	Asp	Pro	Thr	Thr	Trp	
	305					310					315					320	
20	Ser	Ala	Pro	Thr	Leu	Leu	Ala	Thr	Gly	Ile	Cys	Ala	Tyr	Ser	Asp	Leu	
					325					330					335		
25	Gln	Asn	Met	Gly	His	Gly	Pro	Asp	Gly	Ser	Pro	Gln	Phe	Gly	Cys	Leu	
				340					345					350			
30	Tyr	Glu	Ser	Asn	Asn	Tyr	Glu	Glu	Ile	Val	Phe	Leu	Met	Phe	Thr	Leu	
			355					360					365				
35	Lys	Gln	Ala	Phe	Pro	Ala	Val	Phe	Gly	Ala	Gln						
		370					375										
40	<210>	6															
	<211>	21															
	<212>	DNA															
	<213>	Cricetulus	griseus														
45	<400>	6															21
	gggugcaaga	cgacuucagt	t														
50	<210>	7															
	<211>	21															
	<212>	DNA															
	<213>	Cricetulus	griseus														
55	<400>	7															21
	cugaagucgu	cuugcaccct	t														
60	<210>	8															
	<211>	21															
	<212>	DNA															
	<213>	Cricetulus	griseus														
65	<400>	8															21
	ugggacgcug	gaacgagaut	t														
70	<210>	9															
	<211>	21															

	<212> DNA	
	<213> <i>Cricetulus griseus</i>	
5	<400> 9 aucucguucc agcgucccat t	21
	<210> 10	
	<211> 21	
10	<212> DNA	
	<213> <i>Cricetulus griseus</i>	
	<400> 10 ggacacuacg cgucaucugt t	21
15	<210> 11	
	<211> 21	
	<212> DNA	
	<213> <i>Cricetulus griseus</i>	
20	<400> 11 cagaugacgc guagugucct t	21
	<210> 12	
25	<211> 21	
	<212> DNA	
	<213> <i>Cricetulus griseus</i>	
	<400> 12 ccugggugug uaccucaaut t	21
30	<210> 13	
	<211> 21	
	<212> DNA	
35	<213> <i>Cricetulus griseus</i>	
	<400> 13 auugagguac acaccaggt t	21
40	<210> 14	
	<211> 21	
	<212> DNA	
	<213> <i>Cricetulus griseus</i>	
45	<400> 14 gacggaugag caugcagaut t	21
	<210> 15	
	<211> 21	
50	<212> DNA	
	<213> <i>Cricetulus griseus</i>	
	<400> 15 aucugcaugc ucauccguct t	21
55	<210> 16	
	<211> 21	

<212> DNA  
 <213> *Cricetulus griseus*

<400> 16  
 gggaccaccu accggauuct t 21

<210> 17  
 <211> 21  
 <212> DNA  
 <213> *Cricetulus griseus*

<400> 17  
 gaauccggua gguggucct t 21

<210> 18  
 <211> 21  
 <212> DNA  
 <213> *Cricetulus griseus*

<400> 18  
 guaccagccg uguguuacut t 21

<210> 19  
 <211> 21  
 <212> DNA  
 <213> *Cricetulus griseus*

<400> 19  
 aguaacacac ggcugguact t 21

## Claims

1. A cell line, the cell line comprising disrupted expression of at least one chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase, the amino acid sequence of the non-cytoplasmic sialidase being (a) at least 80% identical to SEQ ID NO:4 and/or (b) at least 95% identical to SEQ ID NO:2, wherein the expression of the nucleic acid sequence encoding the non-cytoplasmic sialidase is disrupted by gene targeting.
2. The cell line of claim 1, wherein the gene targeting technique used to disrupt the expression of the nucleic acid sequence encoding the non-cytoplasmic sialidase is selected from the group consisting of homologous recombination and site-specific recombination.
3. The cell line of claim 1 or claim 2, comprising disrupted expression of a chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase having an amino acid sequence at least 90% identical to SEQ ID NO:4.
4. The cell line of any of claims 1 to 3, comprising disrupted expression of a chromosomally integrated nucleic acid sequence encoding a non-cytoplasmic sialidase having an amino acid sequence at least 97% identical to SEQ ID NO:2.
5. The cell line of claim 1 or claim 2, wherein the amino acid sequence of the non-cytoplasmic sialidase consists of SEQ ID NO:4.
6. The cell line of claim 1 or claim 2, wherein the amino acid sequence of the non-cytoplasmic sialidase consists of SEQ ID NO:2..

7. The cell line of any one of the preceding claims, further comprising disrupted expression of a chromosomally integrated nucleic acid sequence encoding a cytoplasmic sialidase, the amino acid sequence of the cytoplasmic sialidase being at least 85% identical to SEQ ID NO:5.

5 8. The cell line of claim 7, wherein the amino acid sequence of the cytoplasmic sialidase consists of SEQ ID NO:5.

9. The cell line of claim 7 or claim 8, wherein the expression of the nucleic acid sequence encoding the cytoplasmic sialidase is disrupted by a technique selected from the group consisting of RNA interference, homologous recombination, and site-specific recombination.

10 10. The cell line of claim 9, wherein RNA interference (RNAi) is mediated by an RNAi agent selected from the group consisting of short interfering RNA, a short hairpin RNA, and an RNAi expression vector.

15 11. The cell line of claim any one of the preceding claims, wherein the cell line is selected from the group consisting of an insect cell line, a mammalian cell line, a rodent cell line, a non-human primate cell line, and a human cell line.

12. The cell line of claim 11, wherein the cell line is a Chinese hamster ovary (CHO) cell line

20 13. A method for producing a glycoprotein, the method comprising expressing a nucleic acid sequence encoding the glycoprotein in a cell of a cell line according to any one of the preceding claims, wherein the glycoprotein has increased sialylation relative to a suitable control.

25 14. The method of claim 13 wherein the nucleic acid sequence encoding the glycoprotein is selected from the group consisting of being chromosomally integrated and being extrachromosomal.

15. A nucleic acid encoding a polypeptide whose amino acid sequence consists of SEQ ID NO 2 or SEQ ID NO 4.

30 16. A polypeptide whose amino acid sequence consists of SEQ ID NO 2 or SEQ ID NO 4.

35



40


45

50


55





**FIG. 1****FIG. 2**





**FIG. 3**




**FIG. 4**


**A****B****FIG. 5**

**FIG. 5C****FIG. 6**



**A**




**B**





**FIG. 7**

**FIG. 7C****FIG. 8**


**FIG. 9**



**FIG. 10**



**FIG. 11A**



**FIG. 11B**



## EUROPEAN SEARCH REPORT

 Application Number  
EP 15 16 3041

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2006/113743 A2 (MASSACHUSETTS INST TECHNOLOGY [US]; NGANTUNG FREDERYK [US]; WANG DANIE) 26 October 2006 (2006-10-26)	1-6, 11-16	INV. C12P21/04 C12P21/06
A	* paragraphs [0007], [0078], [0129], [0132], [0147]; examples 2,3 *	7-10	C12N15/113 C12N9/24
A	MAGESH S ET AL: "Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: Hints for the design of selective NEU3 inhibitors", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 25, no. 2, 1 October 2006 (2006-10-01), pages 196-207, XP028031271, ISSN: 1093-3263, DOI: 10.1016/J.JMGM.2005.12.006 [retrieved on 2006-10-01] * page 196, column 2; figure 1 *	1-6, 11-16	
A	CARRILLO M B ET AL: "Cloning and characterization of a sialidase from the murine histocompatibility-2 complex low levels of mRNA and a single amino acid mutation are responsible for reduced sialidase activity in mice carrying the Neu+alpha allele", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 7, no. 7, 1 January 1997 (1997-01-01), pages 975-986, XP003011683, ISSN: 0959-6658, DOI: 10.1093/GLYCOB/7.7.975 * the whole document *	1-16	C12N
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of the search 7 August 2015	Examiner Gundlach, Björn
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.02 (P04C01)



## EUROPEAN SEARCH REPORT

 Application Number  
EP 15 16 3041

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	<p>HASEGAWA TAKAFUMI ET AL: "Differential expression of three sialidase genes in rat development", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 280, no. 3, 26 January 2001 (2001-01-26), pages 726-732, XP008149387, ISSN: 0006-291X, DOI: 10.1006/BBRC.2000.4186 [retrieved on 2002-03-11] * the whole document *</p> <p>-&amp; ANONYMOUS: "UNIPROT:Q99PW5", 20011116</p> <p>, 16 November 2001 (2001-11-16), page 1, XP007920309, Retrieved from the Internet: URL:http://ibis.internal.epo.org/exam/dbfetch.jsp?id=UNIPROT:Q99PW5 * the whole document *</p> <p>-&amp; ANONYMOUS: "UNIPROT:Q99PW3", 20011116</p> <p>, 16 November 2001 (2001-11-16), page 1, XP007920310, Retrieved from the Internet: URL:http://ibis.internal.epo.org/exam/dbfetch.jsp?id=UNIPROT:Q99PW3 * the whole document *</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-16	<div>TECHNICAL FIELDS SEARCHED (IPC)</div>
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
The Hague		7 August 2015	Gundlach, Björn
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.02 (P04C01)



## EUROPEAN SEARCH REPORT

Application Number  
EP 15 16 3041

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	MIYAGI T ET AL: "BIOCHEMICAL AND IMMUNOLOGICAL STUDIES ON TWO DISTINCT GANGLIOSIDE-HYDROLYZING SIALIDASES FROM THE PARTICULATE FRACTION OF RAT BRAIN", JOURNAL OF BIOCHEMISTRY, JAPANESE BIOCHEMICAL SOCIETY / OXFORD UNIVERSITY PRESS, TOKYO; JP, vol. 107, no. 5, 1 May 1990 (1990-05-01), pages 787-793, XP002913965, ISSN: 0021-924X * the whole document *	1-16	
A	US 2003/014493 A1 (SAKURAI TOSHIYUKI [JP] ET AL) 16 January 2003 (2003-01-16) * the whole document * *	1-16	
A	WO 2007/102432 A1 (KYOWA HAKKO KOGYO KK [JP]; MORI KATSUHIRO; SATOH MITSUO; KANDA YUTAKA) 13 September 2007 (2007-09-13) * the whole document *	1-16	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search		Date of completion of the search	Examiner
The Hague		7 August 2015	Gundlach, Björn
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.02 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 15 16 3041

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-08-2015

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006113743 A2	26-10-2006	US 2009203055 A1 WO 2006113743 A2	13-08-2009 26-10-2006
US 2003014493 A1	16-01-2003	NONE	
WO 2007102432 A1	13-09-2007	NONE	

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

### Non-patent literature cited in the description

- **AUSUBEL et al.** Current Protocols in Molecular Biology. John Wiley & Sons, 2003 [0032]
- **SAMBROOK ; RUSSELL.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, 2001 [0032]
- **CAPECCHI.** *Cell*, 1980, vol. 22, 4779-488 [0034]
- **SMITHIES.** *Proc Natl Acad Sci USA*, 1994, vol. 91, 3612-3615 [0034]
- Protein Purification Techniques: A Practical Approach. Oxford University Press, 2001 [0044]
- **ALTSCHUL et al.** *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0052]
- **KARLIN ; ALTSCHUL.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 87, 2264-2268 [0052]
- **ALTSCHUL et al.** *Nucleic Acids Res.*, 1997, vol. 25, 3389-3402 [0052]
- **FERRARI et al.** *Glycobiology*, 1994, vol. 4 (3), 367-373 [0060]
- **GRAMER et al.** *Biotechnol Prog*, 1993, vol. 9, 366-373 [0061]